Physical Health in Schizophrenia and Role of Clinical Pharmacist: A Narrative Review

被引:0
|
作者
Deepak, C. G. [1 ]
Joel, Juno Jerold [1 ]
Bhat, Shrinivasa Undaru [2 ]
机构
[1] NITTE, NGSM Inst Pharmaceut Sci, Dept Pharm Practice, Mangalore 575018, Karnataka, India
[2] NITTE, KS Hegde Med Acad, Dept Psychiat, Mangaluru, Karnataka, India
关键词
Schizophrenia; Physical illness; Cardiovascular diseases; Metabolic diseases; Clinical pharmacist; MANAGEMENT;
D O I
10.5530/jyp.2024.16.78
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Schizophrenia is a complex psychiatric disease with an unknown aetiology affecting the biological functions of the brain. It is a psychiatric condition affecting both genders irrespective of race, social class and residential status. Globally lifetime of disease is 0.4%, with a 2.5% mortality rate. Schizophrenic patients die at a young age, about 15-20 years earlier than the general population. Premature death in schizophrenic patients is mainly due to physical illness in the form of cardiovascular and metabolic diseases. Seventy-five percent of patients with a diagnosis of schizophrenia exhibit a minimum of one physical illness and it is more complicated if symptoms are severe. Long-term drug therapy is an eminent risk factor for developing physical illnesses. There is no known cure for schizophrenia; thus, it requires lifelong treatment with antipsychotics. Second-Generation Antipsychotics (SGAs), except clozapine are the first-line drugs for treating schizophrenia. These agents are likely to develop cardiovascular and metabolic side effects like hypertension, hyperlipidemia, weight gain, diabetes mellitus and obesity. Another contributing factor is a sedentary lifestyle. Ignoring these factors while undergoing treatment may result in increased burden, decreased quality of life and shorter life expectancy. Clinical pharmacists have a vital role in managing these patients through proper counselling and medication monitoring for better control of the illness.
引用
收藏
页码:607 / 612
页数:6
相关论文
empty
未找到相关数据